BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36039398)

  • 21. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerenkov luminescence imaging of medical isotopes.
    Ruggiero A; Holland JP; Lewis JS; Grimm J
    J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
    Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
    Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
    Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis.
    Freise AC; Zettlitz KA; Salazar FB; Tavaré R; Tsai WK; Chatziioannou AF; Rozengurt N; Braun J; Wu AM
    J Nucl Med; 2018 Jun; 59(6):980-985. PubMed ID: 29326360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET/CT Imaging of Human TNFα Using [
    Beckford-Vera DR; Gonzalez-Junca A; Janneck JS; Huynh TL; Blecha JE; Seo Y; Li X; VanBrocklin HF; Franc BL
    Mol Imaging Biol; 2020 Feb; 22(1):105-114. PubMed ID: 31065895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
    Molecules; 2020 May; 25(10):. PubMed ID: 32429033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
    Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
    J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.
    Hong H; Severin GW; Yang Y; Engle JW; Zhang Y; Barnhart TE; Liu G; Leigh BR; Nickles RJ; Cai W
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):138-48. PubMed ID: 21909753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical
    Chomet M; Schreurs M; Bolijn MJ; Verlaan M; Beaino W; Brown K; Poot AJ; Windhorst AD; Gill H; Marik J; Williams S; Cowell J; Gasser G; Mindt TL; van Dongen GAMS; Vugts DJ
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):694-707. PubMed ID: 32889615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive
    Peplau E; De Rose F; Reder S; Mittelhäuser M; Scafetta G; Schwaiger M; Weber WA; Bartolazzi A; Skerra A; D'Alessandria C
    Thyroid; 2020 Sep; 30(9):1314-1326. PubMed ID: 32200708
    [No Abstract]   [Full Text] [Related]  

  • 34. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
    Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
    Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Park JW; Jung KH; Lee JH; Moon SH; Cho YS; Lee KH
    Sci Rep; 2021 Feb; 11(1):3876. PubMed ID: 33594192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody.
    Deboer MD; Steinman J; Li Y
    J Gastroenterol; 2012 Jun; 47(6):647-54. PubMed ID: 22322660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-administration of Lactobacillus gasseri KBL697 and tumor necrosis factor-alpha inhibitor infliximab improves colitis in mice.
    Han DH; Kim WK; Lee C; Park S; Lee K; Jang SJ; Ko G
    Sci Rep; 2022 Jun; 12(1):9640. PubMed ID: 35688918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A radiopharmaceutical [
    Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
    Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease.
    Rezazadeh F; Ramos N; Saliganan AD; Al-Hallak N; Chen K; Mohamad B; Wiesend WN; Viola NT
    J Nucl Med; 2023 Nov; 64(11):1806-1814. PubMed ID: 37474270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis.
    Park BN; Kim GH; Ko SA; Shin GH; Lee SJ; An YS; Yoon JK
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.